Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.50 |
| ▸ | METAP1 | P53582 | 4/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29850498 | 0.78 | ACHE (0.58) | ACHEMETAP1CYP19A1TSHR | |
| SCHEMBL1567503 | 0.78 | ACHE (0.58) | ACHEMETAP1CYP19A1TSHR | |
| Hydrochloric Acid SCHEMBL6601125 | 0.76 | ACHE (0.56) | ACHEMETAP1HTR7CYP19A1TSHR | |
| SCHEMBL5175924 | 0.75 | HRH3 (0.51) | ACHEMETAP1 | |
| SCHEMBL5175319 | 0.75 | ACHE (0.53) | ACHEMETAP1 | |
| SCHEMBL3602309 | 0.75 | ACHE (0.46) | ACHEMETAP1CYP19A1TSHR | |
| SCHEMBL942998 | 0.75 | ACHE (0.46) | ACHEMETAP1SMN1; SMN2CYP19A1TSHR | |
| SCHEMBL9248465 | 0.74 | ACHE (0.53) | ACHEMETAP1SMN1; SMN2CYP19A1TSHR | |
| SCHEMBL15670682 | 0.74 | ACHE (0.53) | ACHEMETAP1HTR7CYP19A1TSHR | |
| SCHEMBL10710886 | 0.73 | ACHE (0.45) | ACHEMETAP1SMN1; SMN2CYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101121702-A | Phenoxy indanone derivatives containing alkylamino side-chain, preparation method and use thereof | UNIV ZHEJIANG (CN) | 2008-02-13 | — | — | CN | claimed |
| CN-100364961-C | Phenoxyhydrindone derivatives containing nitrogen and preparation and use thereof | UNIV ZHEJIANG (CN) | 2008-01-30 | — | — | CN | claimed |
| US-20060182731-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-08-17 | — | — | US | claimed |
| US-20060167028-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2006-07-27 | — | — | US | claimed |
| CN-1680279-A | Phenoxyhydrindone derivatives containing nitrogen and preparation and use thereof | UNIV ZHEJIANG (CN) | 2005-10-12 | — | — | CN | claimed |
| EP-4021391-B1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | UNILEVER GLOBAL IP LTD (GB) | 2024-01-17 | — | — | EP | disclosed |
| US-20220313581-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | Conopco, Inc. , d/b/a UNILEVER (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220280405-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | Conopco, Inc. , d/b/a UNILEVER (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4021899-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | Unilever Global IP Limited (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-4021391-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | Unilever Global IP Limited (GB) | 2022-07-06 | — | — | EP | disclosed |
| WO-2021037759-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | UNILEVER GLOBAL IP LIMITED (GB) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021037750-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | UNILEVER GLOBAL IP LIMITED (GB) | 2021-03-04 | — | — | WO | disclosed |
| CN-101121702-A | Phenoxy indanone derivatives containing alkylamino side-chain, preparation method and use thereof | UNIV ZHEJIANG (CN) | 2008-02-13 | — | — | CN | disclosed |
| CN-100364961-C | Phenoxyhydrindone derivatives containing nitrogen and preparation and use thereof | UNIV ZHEJIANG (CN) | 2008-01-30 | — | — | CN | disclosed |
| CN-100364961-C | Phenoxyhydrindone derivatives containing nitrogen and preparation and use thereof | UNIV ZHEJIANG (CN) | 2008-01-30 | — | — | CN | disclosed |
| CN-1277809-C | Benzal indone and benzyl indone derivative(s), and its preparing method and use | UNIV ZHEJIANG (CN) | 2006-10-04 | — | — | CN | disclosed |
| US-20060182731-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-08-17 | — | — | US | disclosed |
| US-20060167028-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2006-07-27 | — | — | US | disclosed |
| CN-1709860-A | Benzal indone and benzyl indone derivative(s), and its preparing method and use | UNIV ZHEJIANG (CN) | 2005-12-21 | — | — | CN | disclosed |
| CN-1680279-A | Phenoxyhydrindone derivatives containing nitrogen and preparation and use thereof | UNIV ZHEJIANG (CN) | 2005-10-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280405-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | CUTA, NQO1, TYR | ACHE 168/4885METAP1 1510/4885DDB1 793/4885 |
| US-20220313581-A1 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | TYR, LRAT, NQO1 | ACHE 129/4885METAP1 1218/4885DDB1 568/4885 |
| US-20060167028-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | TEK, FLT4, FLT1 | ACHE 2361/4885METAP1 2271/4885DDB1 4172/4885 |
| US-20060182731-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | TEK, FLT4, FLT1 | ACHE 2361/4885METAP1 2271/4885DDB1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.